NASDAQ:DXCM - DexCom Stock Price, Forecast & News

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings results on Thursday, February, 13th. The medical device company reported $1.15 EPS for the quarter, topping the Zacks' consensus estimate of $0.74 by $0.41. The medical device company had revenue of $462.80 million for the quarter, compared to analyst estimates of $457 million. DexCom had a return on equity of 22.65% and a net margin of 6.85%. View DexCom's Earnings History.

DexCom is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for DexCom.

DexCom updated its FY 2020 After-Hours earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.725-1.775 billion, compared to the consensus revenue estimate of $1.77 billion.

18 brokers have issued twelve-month price targets for DexCom's shares. Their forecasts range from $125.00 to $300.00. On average, they expect DexCom's share price to reach $259.22 in the next year. This suggests that the stock has a possible downside of 14.4%. View Analyst Price Targets for DexCom.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.

News headlines about DXCM stock have trended extremely negative recently, InfoTrie reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. DexCom earned a news impact score of -4.3 on InfoTrie's scale. They also gave media headlines about the medical device company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for DexCom.

DexCom saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 4,750,000 shares, a decrease of 5.4% from the January 15th total of 5,020,000 shares. Based on an average daily trading volume, of 986,900 shares, the short-interest ratio is presently 4.8 days. Currently, 5.3% of the company's stock are sold short. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Netflix (NFLX), ServiceNow (NOW), Home Depot (HD), Micron Technology (MU), Adobe (ADBE) and Mastercard (MA).

DexCom's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.26%), Jennison Associates LLC (3.78%), Capital World Investors (3.50%), Artisan Partners Limited Partnership (2.06%), Blair William & Co. IL (1.32%) and Fred Alger Management LLC (0.82%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.

DXCM stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Jennison Associates LLC, Victory Capital Management Inc., Victory Capital Management Inc., Janus Henderson Group PLC, Peregrine Capital Management LLC, Columbus Circle Investors and First Trust Advisors LP. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman and Steven Robert Pacelli. View Insider Buying and Selling for DexCom.

DXCM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Fred Alger Management LLC, Beacon Investment Advisory Services Inc., Baird Financial Group Inc., Lord Abbett & CO. LLC, Kornitzer Capital Management Inc. KS, Cubist Systematic Strategies LLC and Blair William & Co. IL. View Insider Buying and Selling for DexCom.

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $302.92.

DexCom has a market capitalization of $27.74 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 2,800 workers across the globe.View Additional Information About DexCom.

The official website for DexCom is http://www.dexcom.com/.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]